March 7th, 2022 – On the basis of more than 15 years of scientific efforts in the lab of Yigal Pinto, he, Eva van Rooij and Margien Boels have now officially founded Phlox Therapeutics B.V. as an Amsterdam UMC spin-off, funded by the FIRST fund.

The name and logo of Phlox resembles the approach that we use to recue cardiomyopathies. Phlox focusses on the development of gene therapies that are able to induce healthy gene expression and reverse the negative effects that are caused by gene imbalance.